Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. [electronic resource]
Producer: 20170808Description: 1112-1118 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antineoplastic Agents -- adverse effects
- Diarrhea -- chemically induced
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Fallopian Tube Neoplasms -- chemistry
- Fatigue -- chemically induced
- Female
- Folate Receptor 1 -- analysis
- Humans
- Hypotension -- chemically induced
- Immunoconjugates -- adverse effects
- Maytansine -- adverse effects
- Middle Aged
- Nausea -- chemically induced
- Ovarian Neoplasms -- chemistry
- Peritoneal Neoplasms -- chemistry
- Platinum Compounds -- therapeutic use
- Response Evaluation Criteria in Solid Tumors
- Retreatment
- Vision Disorders -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.